ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "IL-6R signaling"

  • Abstract Number: 6 • 2019 ACR/ARP Annual Meeting

    A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts

    Ruby Siegel1 and Salahuddin Ahmed 2, 1Washington State University Spokane, Spokane, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA

    Background/Purpose: Interleukin-6 (IL-6) promotes synovial hyperplasia by inducing mediators of adhesion, migration and leukocyte infiltration in rheumatoid arthritis (RA). The extracellular enzymes sulfatase-2 (Sulf-2) and…
  • Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting

    Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)

    Christine Xu1, Patrick Nolain 2, Qiang Lu 3, Anne Paccaly 4, Melitza Iglesias-Rodriguez 5, Gregory St John 6, Chad Nivens 4, Rafael Maldonado 7, Tomonori Ishii 8, Ernest Choy 9 and Vanaja Kanamaluru 3, 1Sanofi, Bridgewater, NJ, 2Sanofi-Aventis, Montpellier, France, 3Sanofi, Bridgewater, 4Regeneron Pharmaceuticals, Inc., Tarrytown, 5Sanofi Genzyme, Cambridge, MA, 6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 7Pompeu Fabra University, Barcelona, Spain, 8Tohoku University Hospital, Sendai, Japan, 9Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
  • Abstract Number: 930 • 2018 ACR/ARHP Annual Meeting

    Joint Location-Specific IL6 and JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)

    Deepa Hammaker1, Gyrid Nygaard1, Amanda Kuhs1, Rizi Ai2, David L. Boyle1, Wei Wang3 and Gary S. Firestein1, 1Medicine, University of California San Diego, La Jolla, CA, 2University of California San Diego, La Jolla, CA, 3Chemistry and Biochemistry, University of California San Diego, La Jolla, CA

    Background/Purpose: Recent studies suggest that epigenetic marks distinguish FLS isolated from different joints in RA. Hip and knee joint-derived FLS, in particular, have distinctive DNA…
  • Abstract Number: 1825 • 2018 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Associated Haploinsufficiency in PTPN2 Enhances Severity of IL-17 Mediated Autoimmune Arthritis

    Mattias N. D. Svensson1, Karen M. Doody2, Shen Yang3, Dennis J. Wu4, Cristiano Sacchetti5, Isabelle Aubry6, Piotr Mydel7, Mitchell Kronenberg8, Michel L. Tremblay9 and Nunzio Bottini2, 1Department of Medicine, University of California San Diego, La Jolla, CA, 2Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 3Medicine, University of California San Diego, La Jolla, CA, 4University of California San Diego, San Diego, CA, 5Rheumatology, University of California San Diego, La Jolla, CA, 6Biochemistry, McGill University, Montreal, QC, Canada, 7University of Bergen, Bergen, Norway, 8Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 9Biochemistry, McGill University, Montréal, QC, Canada

    Background/Purpose: Genetic polymorphisms at the PTPN2 locus, which encodes the tyrosine phosphatase TC-PTP, cause reduced gene expression and are linked to rheumatoid arthritis (RA). PTPN2…
  • Abstract Number: 972 • 2017 ACR/ARHP Annual Meeting

    JAK/STAT Mediated Inhibition of Mir-23a~24-2~27a Cluster Potentiates Activation of CD14+ Monocytes in Treatment-Resistant RA

    Marina Frleta-Gilchrist, Donna McIntyre, Aziza Elmesmari, Lynn Stewart, Derek Baxter, Mariola Kurowska-Stolarska, Derek Gilchrist and Iain B. McInnes, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: While emerging and existing treatments of RA allow better options and clinical outcomes for patients, studies informing drug resistant states and further clinical therapeutic…
  • Abstract Number: 1568 • 2017 ACR/ARHP Annual Meeting

    Existence of IL-6 and IL-17 Mediated Inflammation Amplifier Loop in Reactive Arthritis

    Ramnath Misra1, Sandeep Kumar2, Rajeev Singh3, Abhisek Singh4, Daisuke Kamimura5, Smriti Chaurasia2, Yasunobu Aria6, Tori Austria7, Ratnadeep Mukherjee8, Balachandran Ravindran9, Vikas Agarwal2 and Masaaki Murakami10, 1Clinical Immunology, Sanjay Gandhi Postgraduate of Medical Sciences, Lucknow, India, 2Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3Biochemistry, King George Medical University, Lucknow, India, 4Division of Molecular Neroimmunology, Post Doctoral Fellow, Sapporo, Japan, 5Molecular Neuroimmunology, Lecturer, Sapporo 060-0815,, Japan, 6Division of Molecular Neuroimmunology, Assistant Professor, Sapporo 060-0815, Japan, 7Division of Molecular Neuroimmunology, Special appointed - Assistant Professor, Sapporo 060-0815, Japan, 8Institute of Life Sciences, Ph D student, Bhubaneswar, India, 9Institute of Life Sciences, Distinguished Scientist, Bhubaneswar, India, 10Institute of Genetic Medicine, Director, Sapporo 060-0815, Japan

    Background/Purpose: F759 mice with a single amino-acid substitution in signal transducer subunit of IL-6 receptor gp130 (Y759F) develops arthritisspontaneously due to IL-17A and IL-6 mediated…
  • Abstract Number: 2793 • 2017 ACR/ARHP Annual Meeting

    Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)

    Deepa Hammaker1, Gyrid Nygaard1, David L. Boyle2, Rizi Ai3, Wei Wang4 and Gary S. Firestein5, 1Medicine, UC San Diego, La Jolla, CA, 2University of California San Diego, La Jolla, CA, 3UC San Diego, La Jolla, CA, 4Chemistry and Biochemistry, UC San Diego, La Jolla, CA, 5Medicine, University of California San Diego, La Jolla, CA

    Background/Purpose: Aberrant epigenetic marks in RA FLS contribute to disease pathogenesis and aggressive FLS behavior. Computational data also suggest that RA FLS isolated from different…
  • Abstract Number: 60 • 2016 ACR/ARHP Annual Meeting

    A Single Nucleotide Polymorphism of IL6-Receptor Is Associated with Response to Tocilizumab in Rheumatoid Arthritis: Results from Toci and ROC Studies

    Cécile Luxembourger1, Adeline Ruyssen-Witrand2, Yannick Degboé3, Alain G. Cantagrel1, Arnaud CONSTANTIN4, Philippe Gaudin5, Christian Jorgensen6, Jean-Francis Maillefert7, Hubert Marotte Sr.8, Delphine Nigon9, Daniel Wendling10, Jacques-Eric Gottenberg11 and Yves-marie Pers12, 1Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 2Rheumatology Center, Purpan University Hospital, Toulouse, France, 3Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, 4Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 5Rheumatology, Grenoble University Hospital, France, Grenoble, France, 6Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, 7Rheumatology, University Hospital, Dijon, France, 8CHU de St Etienne, Service de rhumatologie, St Etienne, France, 9CHU Purpan, Toulouse, France, 10Rheumatology, Besançon university hospital, Besançon, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12coordination RIC SUD, Montpellier, France

    Background/Purpose: Biological agents (boDMARDs) have modified the therapeutic management of patients with rheumatoid arthritis (RA). However, boDMARDs can induce sustained remission in only 30% of…
  • Abstract Number: 1029 • 2016 ACR/ARHP Annual Meeting

    Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of Th17-Cell Mediated Autoimmune Arthritis

    Mattias N. D. Svensson1,2, Karen M. Doody1, Cristiano Sacchetti1,2, Dennis J. Wu1, Gisen Kim3, Annelie Hellvard4, Brith Bergum4, Piotr Mydel4, Mitchell Kronenberg3, Michel L. Tremblay5 and Nunzio Bottini1,2, 1Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2Department of Medicine, University of California, San Diego, La Jolla, CA, 3Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 4Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, 5Goodman Cancer Centre, McGill University, Montréal, QC, Canada

    Background/Purpose: Genome-wide association studies have linked polymorphisms in the PTPN2 locus to rheumatoid arthritis (RA). PTPN2 encodes the tyrosine phosphatase TC-PTP, an important regulator of…
  • Abstract Number: 1581 • 2016 ACR/ARHP Annual Meeting

    The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients

    Cesar Diaz-Torne1, Maria A. Ortiz2, Patricia Moya3, M. Victoria Hernández4, Delia Reina5, Ivan Castellvi6, Juan Jose De Agustin7, Diana De La Fuente8, Hector Corominas9,10, Raimon Sanmarti11, Josep Maria De Llobet Zubiaga1 and Silvia Vidal2, 1Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, 2Institut de Recerca Sant Pau, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 5Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 6Rheumatology, Hospital de Sant Pau, Barcelona, Spain, 7Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, 8Rheumatology, Hospital de Viladecans, Barcelona, Spain, 9Rheumatology, Hospital Moises Broggi, Barcelona, Spain, 10Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, 11Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain

    Background/Purpose: Several predictors of response to tocilizumab have been described.  They include a low HAQ, high baseline CRP or NK levels and certain IL-6R polymorphisms.…
  • Abstract Number: 2104 • 2016 ACR/ARHP Annual Meeting

    Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis

    Nekane Terrades-Garcia1, Joana Daradoumis2, Ester Planas-Rigol2, Marc Corbera-Bellalta1, Sergio Prieto-González2, Georgina Espígol-Frigolé2 and Maria C. Cid3, 1Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 2Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 3Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain

    Background/Purpose: IL-6 has been considered a biomarker of disease activity in GCA and a potential therapeutic target. However, the functional role of IL-6 in GCA…
  • Abstract Number: 2155 • 2016 ACR/ARHP Annual Meeting

    Crosstalk Between IL-6 and TNF-Alpha Signaling Pathway in Rheumatoid Arthritis Synovial Fibroblasts

    Alvaro Valin1, Yolanda Ruano2, Manuel J. Del Rey3, Carmen M. García-Herrero3, Eduardo Martín-Guerrero1, Beatriz Bravo4, Juan D. Cañete5, José L. Rodríguez-Peralto2 and Jose L. Pablos3,6, 1Grupo de Enfermedades Inflamatorias y Autoimmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 2Pathology Department, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 3Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 4Servicio de Traumatología y Cirugía Ortopédica, Hospital 12 de Octubre, Madrid, Spain, 5Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, 6Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain

    Background/Purpose:  Although elevated IL-6 and its soluble receptor (sIL6R) have been found in the serum and synovium of arthritic patients, the molecular mechanisms by which…
  • Abstract Number: 2604 • 2016 ACR/ARHP Annual Meeting

    Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients

    Cesar Diaz-Torne1, Juan Jose De Agustin2, Patricia Moya1, Maria A. Ortiz3, Delia Reina4, Carme Moragues5, Sergi Ros6, Emili Gomez7, Enrique Casado Burgos8, Eli Garcia9, Manel Pujol10, Maria Pilar Lisbona Perez11, Andrés Ponce12, V Torrente13, P. Estrada14, Silvia Vidal3 and ECOCAT group, 1Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, 2Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, 3Institut de Recerca Sant Pau, Barcelona, Spain, 4Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 5Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6Rheumatology, Hospital de Viladecans, Viladecans, Spain, 7Rheumatology, Hospital Clínic, Barcelona, Spain, 8Hospital Universitari Parc Taulí, Sabadell, Spain, 9Rheumatology, Hospital de Mollet, Mollet, Spain, 10Hospital Mútua de Terrassa, Terrassa, Spain, 11Rheumatology, Hospital de Sabadell, Sabadell, Spain, 12Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, 13Hospital de L'Hospitalet, L'Hospitalet de Llobregat, Spain, 14Rheumatology, Hospital Moises Broggi, Barcelona, Spain

    Background/Purpose: Management of RA patients has improved in the last two decades in part with the use of ultrasound (US) in daily clinical practice. The…
  • Abstract Number: 92 • 2015 ACR/ARHP Annual Meeting

    Variation at Interleukin-6 Receptor Gene Is Associated to Joint Damage in Rheumatoid Arthritis

    María López-Lasanta1, Antonio Julià1, Joan Maymo2, Benjamin Fernandez Gutierrez3, Inmaculada Ureña4, Francisco J. Blanco5, Juan D. Cañete6, Mercedes Alperi-López7, Alejandro Olivé8, Hector Corominas9, Jesús Tornero10, Alba Erra11, Miriam Almirall12, Nuria Palau13, Ana M. Ortiz Garcia14, Gabriela Avila13, Luis Rodriguez-Rodriguez15, Arnald Alonso1, Raül Tortosa1, Isidoro González-Alvaro16 and Sara Marsal1, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, Hospital del Mar, Barcelona, Spain, 3Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 4Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 5Osteoarticular and Aging Research Lab, INIBIC–Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 6Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain, 7Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, 8Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 9Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 10Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, 11Rheumatology, Rheumatology Hospital San Rafael, Barcelona, Spain, 12Rheumatology Department, Hospital del Mar, Barcelona, Spain, 13Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 14Rheumatology, H.U. La Princesa, Madrid, Spain, 15Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 16Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain

    Background/Purpose: Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint…
  • Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting

    Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients

    Shuntaro Saito1, Katsuya Suzuki1, Kunihiro Yamaoka1 and Tsutomu Takeuchi2, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology